As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. This listing covers adult patients with somatostatin receptor-positive (SSR+) midgut NETs whose disease has progressed on a somatostatin analogue and is unresectable (not removable by surgery).

This important milestone follows the Health Canada approval of LUTATHERA® in January 2019 as the first therapeutic commercial grade Peptide Radioreceptor Radionuclide Therapy (PRRT) for the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive GEP-NETs in adults with progressive disease.

LUTATHERA® is a registered trademark of Advanced Accelerator Applications International S.A.

CNETS will continue provide updates on LUTATHERA® funding in other provinces, please visit: